Following the FDA approval of vusolimogene oderparepvec plus nivolumab, melanoma specialists are preparing for real-world clinical use while rethinking how to design future intratumoral therapy trials.
Michael K. K. Wong, MD, PhD
Advertisement
Articles by Michael K. K. Wong, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
2
Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC
3
Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC
4
Building an Adequate ROS1 Workup With RNA-Based Sequencing
5